Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group

This study sought to investigate biological/clinicopathological characteristics of neuroblastoma, undifferentiated subtype (NBUD).

[1]  A. Look,et al.  Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee , 2013, Pediatric blood & cancer.

[2]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[3]  W. Gerald,et al.  MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  J. Štěrba,et al.  Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma , 2011, Journal of Neuro-Oncology.

[5]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[6]  W. Hartmann,et al.  Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 , 2007, Clinical Cancer Research.

[7]  C. Dang,et al.  c-myc overexpression causes anaplasia in medulloblastoma. , 2006, Cancer research.

[8]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[9]  H. Shimada,et al.  Large cell neuroblastoma , 2004, Cancer.

[10]  Einar Hallberg,et al.  Accumulation of c-Myc and proteasomes at the nucleoli of cells containing elevated c-Myc protein levels , 2003, Journal of Cell Science.

[11]  Hiroyuki Shimada,et al.  Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups , 2002, Cancer.

[12]  D. Stram,et al.  Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors , 2001, Cancer.

[13]  L. Rorke,et al.  MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  P. Schürmann,et al.  C‐MYC expression in medulloblastoma and its prognostic value , 2000, International journal of cancer.

[15]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[16]  Hiroyuki Shimada,et al.  Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.

[17]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[18]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[19]  S. Joos,et al.  Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Stram,et al.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Perkins,et al.  Expression of the c‐Myc Protein in Childhood Medulloblastoma , 1998, Journal of pediatric hematology/oncology.

[22]  S. Cohn,et al.  Advances in the diagnosis and treatment of neuroblastoma , 1998, Current opinion in oncology.

[23]  B. Korf,et al.  myc gene amplification and expression in primary human neuroblastoma. , 1990, Cancer research.

[24]  M. Schwab,et al.  Suppression of MYC by high expression of NMYC in human neuroblastoma cells , 1989, Journal of neuroscience research.

[25]  W. Sadee,et al.  Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. , 1987, Cancer research.

[26]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[27]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[28]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[29]  W. Sieber,et al.  Prognostic Factors in Neuroblastoma , 1971, Annals of surgery.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  H. Shimada,et al.  Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma , 2008, Pathology & Oncology Research.

[32]  D. Stram,et al.  Enlarged and prominent nucleoli may be indicative of MYCN amplification , 2005, Cancer.

[33]  J. Lunec,et al.  Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. , 2001, Medical and pediatric oncology.

[34]  D. Stram,et al.  Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.